泊沙康唑和伊曲康唑与来特莫韦同时给药的临床和药理学考虑。
Clinical and Pharmacological Considerations for Concomitant Administration of Posaconazole and Isavuconazole with Letermovir.
机构信息
Division of Clinical Pharmacology and Toxicology Service, Geneva University Hospitals, Geneva, Switzerland.
Division of General Internal Medicine, Geneva University Hospitals, Geneva, Switzerland.
出版信息
Antimicrob Agents Chemother. 2021 May 18;65(6). doi: 10.1128/AAC.00274-21.
Abstract
We sought in this case-control retrospective study to compare posaconazole and isavuconazole (PCZ and IVC, respectively) plasma trough concentration () levels in high-risk allogeneic hematopoietic cell transplant (HCT) recipients who received letermovir (LET) or not. PCZ/IVC levels were not found to be significantly different between cases and controls, as they were 1.31 mg/liter (median) (interquartile range [IQR], 0.90) versus 1.36 mg/liter (IQR, 1.16) ( = 0.31) and 3.20 mg/liter (IQR, 2.40) versus 2.35 mg/liter (IQR, 1.50) ( = 0.17), respectively. In conclusion, we observed PCZ/IVC levels within the expected range and no significant effect of LET coadministration.
摘要
我们在这项回顾性病例对照研究中比较了接受来特莫韦（LET）或未接受 LET 的高危异基因造血细胞移植（HCT）受者的泊沙康唑和伊曲康唑（PCZ 和 IVC）血药谷浓度（）水平。病例组和对照组之间的 PCZ/IVC 水平没有显著差异，分别为 1.31mg/L（中位数）（四分位距 [IQR]，0.90）与 1.36mg/L（IQR，1.16）（=0.31）和 3.20mg/L（IQR，2.40）与 2.35mg/L（IQR，1.50）（=0.17）。总之，我们观察到 PCZ/IVC 水平在预期范围内，且 LET 联合用药无显著影响。
相似文献
1
Clinical and Pharmacological Considerations for Concomitant Administration of Posaconazole and Isavuconazole with Letermovir.泊沙康唑和伊曲康唑与来特莫韦同时给药的临床和药理学考虑。
Antimicrob Agents Chemother. 2021 May 18;65(6). doi: 10.1128/AAC.00274-21.
2
Effect of letermovir initiation on tacrolimus concentrations among lung transplant recipients receiving concomitant azole antifungal prophylaxis.来氟米特起始治疗对同时接受唑类抗真菌预防治疗的肺移植受者他克莫司浓度的影响。
Transpl Infect Dis. 2024 Apr;26(2):e14267. doi: 10.1111/tid.14267. Epub 2024 Mar 15.
3
Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients.伊曲康唑与伏立康唑作为异基因造血细胞移植受者一线抗真菌预防治疗的疗效和安全性比较。
Med Mycol. 2021 Oct 4;59(10):970-979. doi: 10.1093/mmy/myab025.
4
Clinical considerations on posaconazole administration and therapeutic drug monitoring in allogeneic hematopoietic cell transplant recipients.异基因造血细胞移植受者中泊沙康唑给药和治疗药物监测的临床注意事项。
Med Mycol. 2021 Jul 6;59(7):701-711. doi: 10.1093/mmy/myaa106.
5
Drug interaction between letermovir and voriconazole after allogeneic hematopoietic cell transplantation.异基因造血细胞移植后乐韦莫及伏立康唑的药物相互作用。
Int J Hematol. 2021 Jun;113(6):872-876. doi: 10.1007/s12185-021-03105-x. Epub 2021 Mar 7.
6
A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.一项关于异氟康唑预防异基因造血细胞移植患者侵袭性真菌感染的单中心开放标签试验。
Biol Blood Marrow Transplant. 2020 Jun;26(6):1195-1202. doi: 10.1016/j.bbmt.2020.02.009. Epub 2020 Feb 20.
7
Therapeutic drug monitoring of posaconazole in allogeneic hematopoietic stem cell transplantation patients who develop gastrointestinal graft-versus-host disease.泊沙康唑在发生胃肠道移植物抗宿主病的异基因造血干细胞移植患者中的治疗药物监测。
Antimicrob Agents Chemother. 2012 Oct;56(10):5247-52. doi: 10.1128/AAC.00815-12. Epub 2012 Jul 30.
8
Voriconazole in Hematopoietic Stem Cell Transplantation and Cellular Therapies: Real-World Usage and Therapeutic Level Attainment at a Major Transplantation Center.伏立康唑在造血干细胞移植和细胞治疗中的应用：主要移植中心的真实世界使用情况和治疗水平达标情况。
Transplant Cell Ther. 2022 Aug;28(8):511.e1-511.e10. doi: 10.1016/j.jtct.2022.05.030. Epub 2022 May 24.
9
Effects of Letermovir and/or Methylprednisolone Coadministration on Voriconazole Pharmacokinetics in Hematopoietic Stem Cell Transplantation: A Population Pharmacokinetic Study.来特莫韦和/或甲泼尼龙合并用药对造血干细胞移植患者伏立康唑药代动力学的影响：一项群体药代动力学研究。
Drugs R D. 2021 Dec;21(4):419-429. doi: 10.1007/s40268-021-00365-0. Epub 2021 Oct 15.
10
Posaconazole or isavuconazole as sole or predominant antifungal therapy for COVID-19-associated mucormycosis. A retrospective observational case series.泊沙康唑或伊曲康唑作为 COVID-19 相关毛霉病的单一或主要抗真菌治疗。一项回顾性观察性病例系列研究。
Int J Infect Dis. 2022 Jul;120:177-178. doi: 10.1016/j.ijid.2022.04.009. Epub 2022 Apr 9.
引用本文的文献
1
The Effect of Drug-Drug Interactions on the Pharmacokinetics of Isavuconazole: A Comprehensive Review.药物相互作用对艾沙康唑药代动力学的影响：一项综述
Clin Pharmacol. 2025 Jun 17;17:143-153. doi: 10.2147/CPAA.S526869. eCollection 2025.
2
Isavuconazole Induces Neurodevelopment Defects and Motor Behaviour Impairment in Zebrafish Larvae.伊曲康唑诱导斑马鱼幼鱼神经发育缺陷和运动行为障碍。
Mol Neurobiol. 2024 Dec;61(12):10072-10082. doi: 10.1007/s12035-024-04245-x. Epub 2024 May 24.
3
Comparing the Real-World Use of Isavuconazole to Other Anti-Fungal Therapy for Invasive Fungal Infections in Patients with and without Underlying Disparities: A Multi-Center Retrospective Study.比较在有和没有潜在差异的患者中，伊曲康唑与其他抗真菌疗法在侵袭性真菌感染的真实世界使用情况：一项多中心回顾性研究。
J Fungi (Basel). 2023 Jan 27;9(2):166. doi: 10.3390/jof9020166.
4
Therapeutic Drug Monitoring of Orally Administered Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients.口服更昔洛韦预防异基因造血干细胞移植受者的治疗药物监测。
Antimicrob Agents Chemother. 2022 Aug 16;66(8):e0065722. doi: 10.1128/aac.00657-22. Epub 2022 Jul 25.
本文引用的文献
1
Decrease in voriconazole concentration-to-dose ratio after letermovir initiation: a retrospective, observational study.伏立康唑浓度-剂量比值降低后莱曲莫韦的起始：一项回顾性、观察性研究。
Bone Marrow Transplant. 2021 Apr;56(4):949-951. doi: 10.1038/s41409-020-01093-w. Epub 2020 Oct 25.
2
Clinically significant drug interaction: letermovir and voriconazole.具有临床意义的药物相互作用：来特莫韦与伏立康唑。
J Antimicrob Chemother. 2020 Mar 1;75(3):775-777. doi: 10.1093/jac/dkz499.
3
Novel insights into the complex pharmacokinetics of voriconazole: a review of its metabolism.深入了解伏立康唑复杂的药代动力学：对其代谢的综述。
Drug Metab Rev. 2019 Aug;51(3):247-265. doi: 10.1080/03602532.2019.1632888. Epub 2019 Aug 16.
4
Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy.长期抗真菌治疗期间伏立康唑血药浓度的连续监测。
J Antimicrob Chemother. 2019 Aug 1;74(8):2341-2346. doi: 10.1093/jac/dkz188.
5
Pharmacokinetic drug evaluation of letermovir prophylaxis for cytomegalovirus in hematopoietic stem cell transplantation.来特莫韦预防造血干细胞移植后巨细胞病毒的药代动力学药物评价。
Expert Opin Drug Metab Toxicol. 2018 Dec;14(12):1197-1207. doi: 10.1080/17425255.2018.1550485. Epub 2018 Dec 4.
6
Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases.在侵袭性霉菌病患者的 3 期 SECURE 试验中，伊沙康唑的血药浓度变异性和暴露-反应关系。
J Antimicrob Chemother. 2019 Mar 1;74(3):761-767. doi: 10.1093/jac/dky463.
7
Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials.真实世界实践中的伊曲康唑浓度：与临床试验结果的一致性。
Antimicrob Agents Chemother. 2018 Jun 26;62(7). doi: 10.1128/AAC.00585-18. Print 2018 Jul.
8
Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.伊曲康唑的临床药代动力学和药效学。
Clin Pharmacokinet. 2018 Dec;57(12):1483-1491. doi: 10.1007/s40262-018-0673-2.
9
Pharmacokinetics and Tolerability of Letermovir Coadministered With Azole Antifungals (Posaconazole or Voriconazole) in Healthy Subjects.在健康受试者中，仑伐替尼与唑类抗真菌药（泊沙康唑或伏立康唑）联合用药的药代动力学和耐受性。
J Clin Pharmacol. 2018 Jul;58(7):897-904. doi: 10.1002/jcph.1094. Epub 2018 Mar 26.
10
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.来特莫韦预防造血干细胞移植后巨细胞病毒感染。
N Engl J Med. 2017 Dec 21;377(25):2433-2444. doi: 10.1056/NEJMoa1706640. Epub 2017 Dec 6.
Zotero 插件